晚期非小细胞肺癌中医药联合外治法的临床研究  

Combined External Therapy of Traditional Chinese Medicine in the Treatment of Advanced Non-small Cell Lung Cancer

作　　者：朱丽华[1] 陈尚雅 李和根[1] 赵丽红[1] 田建辉[1] 姚逸临[1] 徐蔚杰[1] 周蕾[1] 周之毅[1] 

机构地区：[1]上海中医药大学附属龙华医院肿瘤科,上海200032

出　　处：《世界中医药》2017年第1期34-36,41,共4页World Chinese Medicine

基　　金：上海市进一步加快中医药事业发展三年行动计划(编号:ZY3-CCCX-3-3023);国家中医药管理局国家中医临床研究基地业务建设科研专项(编号:JDZX2012125);上海中医药领军人才建设项目(编号:IH01.22.003)

摘　　要：目的:评价中医药联合外治法对晚期非小细胞肺癌(Non-small Cell lung Cancer,NSCLC)中医症状及免疫功能的影响。方法:以60例Ⅲb-Ⅳ期NSCLC患者为研究人群,观察路径组与非路径组患者在中医症状量化评分表及外周血T淋巴细胞水平方面的差异。结果:2组治疗后的中医症状评分均低于治疗前,临床路径组显著低于非路径组(P<0.05);2组治疗后CD8^+CD28^+均有所提高,路径组治疗后显著高于治疗前(P<0.05),同时显著高于非路径组(P<0.05)。结论:中医药治疗联合外治法,能有效改善晚期非小细胞肺癌患者临床症状,并可通过改变免疫状态来提高抗肿瘤能力。Objective：To evaluate the effect of combined external therapy of Traditional Chinese Medicine on advanced non-small-cell lung cancer （NSCLC） and body＇s immunity.Methods：Sixty cases of Ⅲ b-Ⅳ NSCLC patients were collected to observe the differences in the TCM symptoms and peripheral blood T lymphocyte level between people included in pathway and not include.Results：After treatment,TCM symptom scores were lower than before treatment in both groups,and the scores of patients treated with pathway is significantly lower than that of patients not included in pathway （P 〈 0.05）.After treatment,CD8 ^＋ CD28 ^＋ both increased in the two groups,and in the treatment group,the level was obviously higher than before treatment,also higher than the control group （P 〈 0.05）.Conclusion：Combined external treatment of traditional Chinese medicine can effectively improve clinical symptoms in patients with advanced NSCLS,and also can improve their anti-tumor ability by improving immuntility.

关 键 词：肺癌 中医症状 CD8^+CD28^+ 

分 类 号：R273[医药卫生—中西医结合] R244[医药卫生—中医肿瘤科]